Changes in myocardial function and the possibility of a regression of left-ventricular hypertrophy were examined in patients with stable hypertension during a year of effective hypotensive treatment. Ninety-seven patients with essential hypertension, stage IIB (by Myasnikov's classification) and aged 35 to 56 years, were studied. Echography was conducted before the onset of treatment and after one year of regular hypotensive therapy. A marked hypotensive effect was noted in the course of treatment. Left-ventricular myocardial weight declined in 69% of patients, remained unchanged in 18.6% and increased in 12.4% despite the hypotensive effect of treatment. The reduction of left-ventricular hypertrophy was associated with no basic changes of myocardial pump function or contractility.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Damage control resuscitation: how it's done and where we can improve. A view of the Brazilian reality according to trauma professionals.
Rev Col Bras Cir
January 2025
- School of Medical Sciences Orebro university, Department of Surgery - Orebro - OR - Suécia.
Introduction: Hemorrhage is the leading cause of preventable deaths in trauma patients, resulting in 1.5 million deaths annually worldwide. Traditional trauma assessment follows the ABC (airway, breathing, circulation) sequence; evidence suggests the CAB (circulation, airway, breathing) approach to maintain perfusion and prevent hypotension.
View Article and Find Full Text PDFGuidance for Prescribing Oral Antihypertensive Medications in the Emergency Department.
Curr Hypertens Rep
January 2025
Department of Emergency Medicine, Integrative Biosciences Center, Wayne State University, Detroit, MI, USA.
Purpose Of Review: To review the most current recommendations regarding assessment and treatment of asymptomatic hypertension treatment in the emergency department (ED) and to provide guidance for prescribing oral antihypertensive therapy for ED providers.
Recent Findings: There are varying management strategies for the treatment of asymptomatic hypertension in the ED likely due to a lack of direct guidelines for treatment. There is an increasing body of evidence for the safety of initiating therapy to treat chronic asymptomatic hypertension in the ED.
[Hypertension : what's new in 2024].
Rev Med Suisse
January 2025
Service de néphrologie et d'hypertension, Centre hospitalier universitaire vaudois, 1005 Lausanne.
The major clinical studies in 2024 reviewed in this manuscript will focus on blood pressure measurement, the effect of coffee on the latter, its follow-up in the postpartum period, blood pressure targets for patients at high cardiovascular risk, particularly those with diabetes, and the late onset of primary aldosteronism after a negative initial confirmation test.
View Article and Find Full Text PDFCarbapenems in the management of valproic acid overdose (MPT-01166-24 R1).
Br J Clin Pharmacol
January 2025
Departments of Medicine, Pediatrics, and Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
Severe valproic acid (VPA) overdose is characterized by coma (sometimes with cerebral oedema), respiratory depression, hypotension and metabolic abnormalities. Traditional management of VPA poisoning has been limited to gastrointestinal decontamination, L-carnitine supplementation and, in severe cases, haemodialysis. Recently, interest has developed in the use of carbapenem antibiotics as an adjunctive therapy in patients with severe VPA poisoning.
View Article and Find Full Text PDFCurrent landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy.
Oncoimmunology
December 2025
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Immune checkpoint blockade (ICB) has significantly improved the survival for many patients with advanced malignancy. However, fewer than 50% of patients benefit from ICB, highlighting the need for more effective immunotherapy options. High-dose interleukin-2 (HD IL-2) immunotherapy, which is approved for patients with metastatic melanoma and renal cell carcinoma, stimulates CD8 T cells and NK cells and can generate durable responses in a subset of patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!